Doctor profile · Federal record

Dr. Mark Jeranko, D.O.

Rheumatology Physician (CMS: Rheumatology) · Rheumatology Physician · Loveland, CO

  • NPI 1114304573
  • Accepts Medicare
  • 11 yrs in practice
  • Licensed in 2 states
  • Male
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
2500 Rocky Mountain Ave Ste 2200
Loveland, CO 805389004
(970) 652-2333
fax (970) 593-9731

Credentials & registration

NPPES · NUCC
NPI registered
May 2015 — 11 yrs on file
Profile last updated
April 10, 2026
Year of graduation
2015 — 11 yrs since
Specialty taxonomy
207RR0500X — NUCC code
State licenses (2)
Colorado #DR.0064290 · Michigan #5101021529

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1114304573. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
18,169
Distinct HCPCS
10
Medicare allowed
$277,130
HCPCS Description Services Patients Avg allowed
J3262 Injection, tocilizumab, 1 mg 13,360 14 $6
J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) 2,125 20 $43
J1745 Injection, infliximab, excludes biosimilar, 10 mg 1,380 24 $33
J0897 Injection, denosumab, 1 mg 720 12 $23
99214 Established patient office or other outpatient visit, 30-39 minutes 118 88 $127
96413 Administration of chemotherapy into vein, 1 hour or less 81 59 $136
J7050 Infusion, normal saline solution, 250 cc 74 50 $1
J3489 Injection, zoledronic acid, 1 mg 70 14 $10
96415 Administration of chemotherapy into vein, each additional hour 68 40 $29
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 63 48 $66

In context: peer comparison

Among 1 peers in Loveland Rheumatology Physician, average services per provider: 1,297. This provider delivers 14× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$1,450
Transactions
59
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Amgen INC. 21 $582.72
Ucb, INC. 11 $258.69
AstraZeneca Pharmaceuticals Lp 6 $165.80
Lilly USA, LLC 4 $70.01
Abbvie INC. 2 $47.58
Pfizer INC. 2 $47.12
Ani Pharmaceuticals, INC. 2 $42.18
Janssen Biotech, INC. 2 $38.54
Radius Health, INC. 2 $37.27
Kiniksa Pharmaceuticals International, Plc 2 $34.39
Novartis Pharmaceuticals Corporation 1 $26.97
Boehringer Ingelheim Pharmaceuticals, INC. 1 $26.22
Celltrion USA INC. 1 $22.50
Scilex Pharmaceuticals INC. 1 $16.66
E.R. Squibb & Sons, L.L.C. 1 $16.64

By nature of payment

Food and Beverage
$1,450

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
615
Patients
260
Total drug cost
$437,647
Drug Type Claims Patients Total cost
Methotrexate (Methotrexate Sodium) Brand 121 65 $4,106
Prednisone Generic 113 72 $1,178
Hydroxychloroquine Sulfate Generic 77 37 $4,837
Allopurinol Generic 51 20 $1,251
Alendronate Sodium Generic 39 12 $325
Folic Acid Generic 31 14 $198
Gabapentin Generic 29 14 $798
Enbrel Sureclick (Etanercept) Brand 26 0 $196,809
Sulindac Generic 23 12 $806
Meloxicam Generic 21 14 $170

Frequently asked questions

Auto-generated from federal data
What is Dr. Mark Jeranko's medical specialty?
Dr. Mark Jeranko practices Rheumatology Physician in Loveland, CO.
Where does Dr. Mark Jeranko practice?
Dr. Mark Jeranko practices at 2500 Rocky Mountain Ave Ste 2200, Loveland, CO 805389004. Office phone: 9706522333.
What is Dr. Mark Jeranko's NPI?
Dr. Mark Jeranko's National Provider Identifier (NPI) is 1114304573, issued by NPPES.
Does Dr. Mark Jeranko accept Medicare assignment?
Yes. Dr. Mark Jeranko accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Mark Jeranko commonly perform?
Top Medicare-reported procedures in 2023: Injection, tocilizumab, 1 mg (HCPCS J3262); Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129); Injection, infliximab, excludes biosimilar, 10 mg (HCPCS J1745). Source: CMS Medicare Physician & Other Practitioners file.